Checked.be
Active
BE 0403.096.168Public limited company
UCB PHARMA
Researchdreef 60 ·1070 Anderlecht, Belgium· 58 yrs active
Sector: Wholesale trade
(46460)
Conclusion
The computed 12-month bankruptcy probability of UCB PHARMA is 0.9% (low). The company has been active since 1968 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
Based on State Gazette and CBE data.
Key figures
| Active | 58 yrs |
| Board | 6 |
| Locations | 3 |
| Publications | 48 |
Bankruptcy probability (12 mo)
0.9%
Low
0%0,5%1,5%4%10%≥25%
Long track record
−Higher-failure-rate region
+Multiple establishment units
+
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Risk Assessment
0 / 100
Low riskTrust signals
Long-established
Founded in 1968, 58 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags
No administrative flags
Financial overview
Financials being processed
NBB has 10 filing(s) on record for this company, latest fiscal year 2025 (volledig). The annual accounts are being processed.
Filings on record
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | volledig | 19-05-2026 | 2026-00115119 |
| 31-12-2024 | volledig | 19-05-2025 | 2025-00100129 |
| 31-12-2023 | volledig | 13-05-2024 | 2024-00086900 |
| 31-12-2022 | volledig | 17-05-2023 | 2023-00088919 |
| 31-12-2021 | volledig | 23-05-2022 | 2022-20031616 |
| 31-12-2020 | volledig | 30-04-2021 | 2021-12100056 |
| 31-12-2019 | volledig | 18-05-2020 | 2020-12200596 |
| 31-12-2018 | volledig | 10-05-2019 | 2019-12900344 |
| 31-12-2017 | volledig | 28-05-2018 | 2018-13900568 |
| 31-12-2016 | volledig | 22-05-2017 | 2017-13000228 |
Directors & mandates
Current directors & mandates
-
Current26-07-2024 → present
-
Current04-08-2023 → present
4 events
- 04-08-2023 Mandate renewed· Director
- 01-07-2023 Resigned· Director
- 23-06-2020 Mandate renewed· Director
- 30-05-2017 Appointed· Director
-
Current19-10-2020 → present
-
Current18-07-2019 → present
2 events
- 23-06-2022 Mandate renewed· Director
- 18-07-2019 Appointed· Director
-
Current27-08-2018 → present
3 events
- 23-06-2022 Mandate renewed· Director
- 07-06-2019 Mandate renewed· Director
- 27-08-2018 Appointed· Director
-
Current17-03-2014 → present
6 events
- 04-08-2023 Mandate renewed· Director
- 23-06-2020 Mandate renewed· Director
- 30-05-2017 Mandate renewed· Director
- 10-06-2014 Appointed· Director
- 10-06-2014 Mandate renewed· Director
- 17-03-2014 Appointed· Director
Historic, not recently confirmed (1)
These mandates remain open in the register but have not been confirmed by a new act in over six years. They do not count as active directors.
-
Not recently confirmedlast confirmed in an act from 2005
Former directors (16)
-
Former22-11-2019 → 26-07-2024
2 events
- 26-07-2024 Resigned· Managing director
- 22-11-2019 Appointed· Daily management
-
Former01-04-2015 → 19-10-2020
2 events
- 19-10-2020 Resigned· Daily management
- 01-04-2015 Appointed· Daily management
-
Former26-03-2012 → 31-03-2019
3 events
- 31-03-2019 Resigned· Director
- 15-01-2016 Appointed· Director
- 26-03-2012 Appointed· Managing director
-
Former26-03-2012 → 19-04-2018
4 events
- 19-04-2018 Resigned· Director
- 01-04-2018 Resigned· Daily management
- 15-01-2016 Appointed· Director
- 26-03-2012 Appointed· Managing director
-
Former10-06-2014 → 10-05-2017
2 events
- 10-05-2017 Resigned· Director
- 10-06-2014 Mandate renewed· Director
-
Former10-06-2014 → 31-12-2016
2 events
- 31-12-2016 Resigned· Director
- 10-06-2014 Mandate renewed· Director
-
Former17-01-2013 → 15-01-2016
2 events
- 15-01-2016 Resigned· Director
- 17-01-2013 Appointed· Director
-
Former11-06-2012 → 15-01-2016
3 events
- 15-01-2016 Resigned· Director
- 09-06-2015 Mandate renewed· Director
- 11-06-2012 Mandate renewed· Director
-
Former17-06-2010 → 15-01-2016
4 events
- 15-01-2016 Resigned· Director
- 09-06-2015 Mandate renewed· Director
- 11-06-2012 Mandate renewed· Director
- 17-06-2010 Appointed· Director
-
Former- → 09-06-2015
-
Former10-06-2014 → 31-01-2015
2 events
- 31-01-2015 Resigned· Director
- 10-06-2014 Mandate renewed· Director
-
Former11-06-2012 → 17-03-2014
2 events
- 17-03-2014 Resigned· Director
- 11-06-2012 Mandate renewed· Director
-
Former11-06-2012 → 01-01-2013
2 events
- 01-01-2013 Resigned· Director
- 11-06-2012 Mandate renewed· Director
-
Former- → 26-03-2012
-
Former- → 17-06-2010
-
Former- → 03-08-2005
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.
Statutory auditor
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRLCurrent Statutory auditor · represented by Sébastien Schueremans |
- | 26-08-2024 → present |
| Forvis Mazars Réviseurs d’Entreprises Statutory auditor · represented by Anton Nuttens succeeded by Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL in 2024 |
- | 01-07-2021 → 26-08-2024 |
| PwC Reviseurs d'Entreprises Company auditor · represented by Romain SEFFER succeeded by Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL in 2024 |
- | 18-12-2020 → 26-08-2024 |
| PwC Réviseurs d'Entreprises SRL Statutory auditor · represented by Romain Seffer |
- | - → 01-07-2021 |
| SCCRL PwC Réviseurs d'Entreprises Statutory auditor · represented by Romain Seffer succeeded by PwC Reviseurs d'Entreprises in 2020 |
- | 11-06-2012 → 18-12-2020 |
Appointed statutory auditor from the Belgian State Gazette. The IRE/IBR number refers to the register of the Institute of Registered Auditors.
Legal Structure
| NACE primary | Wholesale trade(46460) |
| Legal form | Public limited company(014) |
| Incorporation | 01-02-1968 |
| Status | Active |
| Postal code | 1070 |
Connections & network
Group structure
Parent · 351 subsidiaries · 5 locations
Control→
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.
Establishment units
UCB PHARMA
since 19682.037.631.587
UCB PHARMA
since 20062.159.107.459
UCB Pharma
since 20232.342.005.216
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Real-estate footprint
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
Flanders
1
(33.3%)
Wallonia
1
(33.3%)
Brussels
1
(33.3%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25743G0274/00E002 | Wallonia | 18.8 ha | 1 · 1,486 m² | 9.4 m · 2 fl. |
| 21307F0123/00P000 | Brussels | 3.9 ha | 1 · 4,201 m² | 18.7 m · 4 fl. |
| 24040B0224/00B000 | Flanders | 1.2 ha | 1 · 1,724 m² | - |
Methodology
via registered seat: 1 · via establishment units: 2
3 of 3 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
2026
19-05-2026
NBB filing
Annual accounts filed
2025
17-10-2025
State Gazette act
Director changes
22-07-2025
State Gazette act
Verified v1
19-05-2025
NBB filing
Annual accounts filed
2024
26-08-2024
State Gazette act
Director changes
13-05-2024
NBB filing
Annual accounts filed
2023
04-08-2023
State Gazette act
Director changes
04-08-2023
State Gazette act
Director changes
17-05-2023
NBB filing
Annual accounts filed
11-05-2023
State Gazette act
Verified v1
11-05-2023
State Gazette act
Verified v1
2022
28-07-2022
State Gazette act
Capital & shares
23-06-2022
State Gazette act
Director changes
23-05-2022
NBB filing
Annual accounts filed
2021
09-07-2021
State Gazette act
Director changes
09-07-2021
State Gazette act
Director changes
09-07-2021
State Gazette act
Director changes
30-04-2021
NBB filing
Annual accounts filed
22-01-2021
State Gazette act
Capital & shares
2020
30-12-2020
State Gazette act
Capital & shares
12-11-2020
State Gazette act
Director changes
23-06-2020
State Gazette act
Director changes
18-05-2020
NBB filing
Annual accounts filed
02-01-2020
State Gazette act
Director changes
2019
23-08-2019
State Gazette act
Director changes
09-07-2019
State Gazette act
Verified v1
09-07-2019
State Gazette act
Verified v1
07-06-2019
State Gazette act
Director changes
10-05-2019
NBB filing
Annual accounts filed
03-05-2019
State Gazette act
Capital & shares
05-02-2019
State Gazette act
Director changes
2018
27-08-2018
State Gazette act
Director changes
28-05-2018
NBB filing
Annual accounts filed
2017
25-09-2017
State Gazette act
Director changes
30-05-2017
State Gazette act
Director changes
22-05-2017
NBB filing
Annual accounts filed
17-02-2017
State Gazette act
Director changes
2016
11-05-2016
State Gazette act
Verified v1
11-04-2016
State Gazette act
Director changes
01-02-2016
State Gazette act
Director changes
2015
09-06-2015
State Gazette act
Director changes
2014
10-06-2014
State Gazette act
Director changes
31-03-2014
State Gazette act
Capital & shares
2013
22-10-2013
State Gazette act
Director changes
08-05-2013
State Gazette act
Verified v1
08-05-2013
State Gazette act
Verified v1
12-04-2013
State Gazette act
Director changes
18-02-2013
State Gazette act
Director changes
2012
11-06-2012
State Gazette act
Director changes
03-05-2012
State Gazette act
Director changes
2010
17-06-2010
State Gazette act
Capital & shares
17-06-2010
State Gazette act
Director changes
04-06-2010
State Gazette act
Capital & shares
31-05-2010
State Gazette act
Verified v1
31-05-2010
State Gazette act
Verified v1
2007
26-03-2007
State Gazette act
Statutes amendment
2005
03-08-2005
State Gazette act
Director changes
2004
24-05-2004
State Gazette act
Capital & shares
Belgisch Staatsblad, acts
Capital history · 8
28-07-2022
v3.2
22-01-2021
v3.2
30-12-2020
v3.2
03-05-2019
v3.2
31-03-2014
v3.2
17-06-2010
v3.2
04-06-2010
v3.2
24-05-2004
v3.2
All acts · 48
updated 9 months ago
2025
17-10-2025 Change in the board of directors
Summary:
v3.2
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}22-07-2025 Board meeting · Statute amendment · General meeting · Officer appointment
- Publication: 22/07/2025 · Algemene Vereniging van de Geneesmiddelenindustrie
- Filing: 11/07/2025 · Algemene Vereniging van de Geneesmiddelenindustrie
- Board meeting: 23/04/2025 · Algemene Vereniging van de Geneesmiddelenindustrie
- Statute amendment: wijziging delegatiereglement dagelijks bestuur · Algemene Vereniging van de Geneesmiddelenindustrie
- General meeting: 11/06/2025 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: bestuurder, start_date: 2025-06-11 · Almirall N.V.
- Officer appointment: role: bestuurder, start_date: 2025-06-11 · Novo Nordisk Pharma N.V.
- Officer appointment: role: bestuurder, start_date: 2025-06-11 · Takeda Belgium N.V.
- Officer reappointment: role: bestuurder, start_date: 2025-06-11 · Amgen N.V.
- Officer reappointment: role: bestuurder, start_date: 2025-06-11 · MSD Belgium N.V.
- Officer reappointment: role: bestuurder, start_date: 2025-06-11 · Roche N.V.
- Officer reappointment: role: bestuurder, start_date: 2025-06-11 · UCB Pharma N.V.
- Officer resignation: role: bestuurder, end_date: 2025-06-11 · Vertex Pharmaceuticals (Netherlands) BV
- Permanent representative: start_date: 16/05/2025 · Paul Lacante
- Permanent representative · Gregory Paton
- Permanent representative · Axel De Muyt
- Permanent representative · Bruno Rabilier
Summary:
Board meeting · Statute amendment · General meeting · Officer appointment
Technical details
{
"facts": [
{
"date": "2025-07-22",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad -22/07/2025 - Annexes du Moniteur belge",
"value": "22/07/2025",
"object": null,
"subject": "e1"
},
{
"date": "2025-07-11",
"type": "filing",
"quote": "neergelegd/ontvangen op 114 JULI 2025",
"value": "11/07/2025",
"object": null,
"subject": "e1"
},
{
"date": "2025-04-23",
"type": "board_meeting",
"quote": "VERGADERING VAN DE RAAD VAN BESTUUR VAN 23 APRIL 2025",
"value": "23/04/2025",
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "Onderwerp akte: Benoeming bestuurders - wijziging delegatiereglement dagelijks bestuur",
"value": "wijziging delegatiereglement dagelijks bestuur",
"object": null,
"subject": "e1"
},
{
"date": "2025-06-11",
"type": "general_meeting",
"quote": "GEWONE ALGEMENE VERGADERING VAN 11 JUNI 2025",
"value": "11/06/2025",
"object": null,
"subject": "e1"
},
{
"date": "2025-06-11",
"type": "officer_appointment",
"quote": "Benoeming van: Almirall N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e2",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_appointment",
"quote": "Benoeming van: Novo Nordisk Pharma N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e3",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_appointment",
"quote": "Benoeming van: Takeda Belgium N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e4",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. Amgen N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e5",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 2. MSD Belgium N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e6",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 3. Roche N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e7",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 4. UCB Pharma N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e8",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"type": "officer_resignation",
"quote": "Ontslag van: 1. Vertex Pharmaceuticals (Netherlands) BV",
"value": {
"role": "bestuurder",
"end_date": "2025-06-11"
},
"object": null,
"subject": "e9",
"_value_raw": {
"role": "bestuurder",
"reason": "ontslag",
"end_date": "11/06/2025"
}
},
{
"date": "2025-05-16",
"type": "permanent_representative",
"quote": "Bristol-Myers Squibb Belgium N.V. ... heeft als nieuwe vaste vertegenwoordiger vanaf 16/05/2025 de heer Paul Lacante",
"value": {
"start_date": "16/05/2025"
},
"object": "e10",
"subject": "e11"
},
{
"type": "permanent_representative",
"quote": "Almirall N.V. ... heeft als vaste vertegenwoordiger de heer Gregory Paton",
"value": {},
"object": "e2",
"subject": "e13"
},
{
"type": "permanent_representative",
"quote": "Novo Nordisk Pharma N.V. ... heeft als vaste vertegenwoordiger de heer Axel De Muyt",
"value": {},
"object": "e3",
"subject": "e14"
},
{
"type": "permanent_representative",
"quote": "Takeda Belgium N.V. ... heeft als vaste vertegenwoordiger de heer Bruno Rabilier",
"value": {},
"object": "e4",
"subject": "e15"
}
],
"act_meta": {
"outcome": "clean",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 9714,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Kantersteen 47, 1000 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0403.090.131",
"kind": "company",
"name": "Almirall N.V.",
"attrs": {
"seat": "Lenneke Marelaan 4, 1932 Sint-Stevens-Woluwe"
}
},
{
"id": "e3",
"kbo": "0414.695.586",
"kind": "company",
"name": "Novo Nordisk Pharma N.V.",
"attrs": {
"seat": "Alfons Gossetlaan 32E/202, 1702 Groot-Bijgaarden"
}
},
{
"id": "e4",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium N.V.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e5",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen N.V.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e6",
"kbo": "0406.820.770",
"kind": "company",
"name": "MSD Belgium N.V.",
"attrs": {
"seat": "Vorstlaan 25, 1170 Watermaal-Bosvoorde"
}
},
{
"id": "e7",
"kbo": "0403.088.151",
"kind": "company",
"name": "Roche N.V.",
"attrs": {
"seat": "Dantestraat 75, 1070 Anderlecht"
}
},
{
"id": "e8",
"kbo": "0403.096.168",
"kind": "company",
"name": "UCB Pharma N.V.",
"attrs": {
"seat": "Researchdreef 60, 1070 Anderlecht"
}
},
{
"id": "e9",
"kbo": "0666.408.905",
"kind": "company",
"name": "Vertex Pharmaceuticals (Netherlands) BV",
"attrs": {
"seat": "Leidsevaart 20, NL - 2013 HA Haarlem"
}
},
{
"id": "e10",
"kbo": "0403.075.184",
"kind": "company",
"name": "Bristol-Myers Squibb Belgium N.V.",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Paul Lacante",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Sally McNab",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Gregory Paton",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Axel De Muyt",
"attrs": {}
},
{
"id": "e15",
"kbo": null,
"kind": "person",
"name": "Bruno Rabilier",
"attrs": {}
},
{
"id": "e16",
"kbo": null,
"kind": "company",
"name": "Facing BV",
"attrs": {}
},
{
"id": "e17",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {}
}
]
}2024
26-08-2024 1 director appointed, 1 resigning, 1 reappointed
- Myriam Juckler, Gedelegeerd bestuurder
- Jacques Marbehant, Gedelegeerd bestuurder
- Sébastien Schueremans, Commissaris
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "commissaris_renew",
"role": "commissaris",
"person": {
"rrn": null,
"name": "S\u00E9bastien Schueremans",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Mazars Bedrijfsrevisoren - R\u00E9viseurs d\u0027Entreprises BV/SRL",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "de nommer Mazars Bedrijfsrevisorer - R\u00E9viseurs d\u0027Entreprises BV/SRL, commissaire aux comptes, dont le mandat expire \u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale des actionnaires de 2024 pour une dur\u00E9e de 3 ans, jusqu\u0027\u00E0 et y compris l\u0027assembl\u00E9e g\u00E9n\u00E9rale annuelle de 2027"
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Myriam Juckler",
"address": null,
"birth_date": null
},
"effective_date": "2024-07-26",
"evidence_quote": "Le Conseil d\u0027Administration a d\u00E9cid\u00E9 d\u0027approuver la nomination de Myriam Juckler, avec effet \u00E0 ce jour, avec adresse professionnelle, Chemin du Foriest 1 \u00E0 1420 Braine-l\u0027Alleud, en qualit\u00E9 de d\u00E9l\u00E9gu\u00E9e charg\u00E9e de la gestion journali\u00E8re de la soci\u00E9t\u00E9"
},
{
"kind": "director_out",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Jacques Marbehant",
"address": null,
"birth_date": null
},
"effective_date": "2024-07-26",
"evidence_quote": "en remplacement de Jacques Marbehant dont les pouvoirs ont \u00E9t\u00E9 r\u00E9voqu\u00E9s \u00E0 ce jour"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}2023
04-08-2023 Change in the board of directors
Summary:
v3.2
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}04-08-2023 1 resigning, 2 reappointed
- Charl van Zyl, Bestuurder
- Jean-Christophe Tellier, Bestuurder
- Charl van Zyl, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean-Christophe Tellier",
"address": null,
"birth_date": null
},
"evidence_quote": "de renouveler les mandats d\u0027administrateurs de Messieurs Jean-Christophe Tellier et Charl van Zyl pour un terme de six ans"
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Charl van Zyl",
"address": null,
"birth_date": null
},
"evidence_quote": "de renouveler les mandats d\u0027administrateurs de Messieurs Jean-Christophe Tellier et Charl van Zyl pour un terme de six ans"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Charl van Zyl",
"address": null,
"birth_date": null
},
"effective_date": "2023-07-01",
"evidence_quote": "Les Actionnaires actent la d\u00E9mission de Chari van Zyl en qualit\u00E9 d\u0027administrateur avec effet au 1 juillet 2023."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}11-05-2023 Act object · General meeting · Officer reappointment · Auditor appointment
- Act object: Benoeming bestuurders en commissaris - Nieuwe vaste vertegenwoordigers van bestuurders - Benoeming voorzitter · Algemene Vereniging van de Geneesmiddelenindustrie
- Filing: 03/05/2023 · Algemene Vereniging van de Geneesmiddelenindustrie
- General meeting: 22/03/2023 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer reappointment: role: bestuurder, start_date: 2023-03-22 · AstraZeneca N.V.
- Officer reappointment: role: bestuurder, start_date: 2023-03-22 · Bristol-Myers Squibb Belgium N.V.
- Officer reappointment: role: bestuurder, start_date: 2023-03-22 · GlaxoSmithKline Pharmaceuticals N.V.
- Officer reappointment: role: bestuurder, start_date: 2023-03-22 · Janssen-Cilag N.V.
- Officer reappointment: role: bestuurder, start_date: 2023-03-22 · Novartis Pharma N.V.
- Officer reappointment: role: bestuurder, start_date: 2023-03-22 · Sanofi Belgium N.V.
- Auditor appointment: role: commissaris, term: drie jaar, start_date: 22/03/2023 · KPMG Bedrijfsrevisoren BV
- Permanent representative: start_date: 01/01/2023 · Xavier Hormaechea
- Permanent representative: start_date: 19/01/2023 · Emmanuelle Boishardy
- Board meeting: 19/04/2023 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: voorzitter van de Raad van Bestuur, start_date: 2023-04-19 · Frédéric Clais
- Permanent representative: end_date: 01/01/2023 · Willy Cnops
- Permanent representative: end_date: 19/01/2023 · Sabena Solomon
Summary:
Act object · General meeting · Officer reappointment · Auditor appointment
Technical details
{
"facts": [
{
"type": "act_object",
"quote": "Onderwerp akte: Benoeming bestuurders en commissaris - Nieuwe vaste vertegenwoordigers van bestuurders - Benoeming voorzitter",
"value": "Benoeming bestuurders en commissaris - Nieuwe vaste vertegenwoordigers van bestuurders - Benoeming voorzitter",
"object": null,
"subject": "e1"
},
{
"date": "2023-05-03",
"type": "filing",
"quote": "neergelegd/ontvangen op 03 MEI 2023",
"value": "03/05/2023",
"object": null,
"subject": "e1"
},
{
"date": "2023-03-22",
"type": "general_meeting",
"quote": "GEWONE ALGEMENE VERGADERING VAN 22 MAART 2023",
"value": "22/03/2023",
"object": null,
"subject": "e1"
},
{
"date": "2023-03-22",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. AstraZeneca N.V.",
"value": {
"role": "bestuurder",
"start_date": "2023-03-22"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "bestuurder",
"start_date": "22/03/2023"
}
},
{
"date": "2023-03-22",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 2. Bristol-Myers Squibb Belgium N.V.",
"value": {
"role": "bestuurder",
"start_date": "2023-03-22"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "bestuurder",
"start_date": "22/03/2023"
}
},
{
"date": "2023-03-22",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 3.GlaxoSmithKline Pharmaceuticals N.V.",
"value": {
"role": "bestuurder",
"start_date": "2023-03-22"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "bestuurder",
"start_date": "22/03/2023"
}
},
{
"date": "2023-03-22",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 4.Janssen-Cilag N.V.",
"value": {
"role": "bestuurder",
"start_date": "2023-03-22"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "bestuurder",
"start_date": "22/03/2023"
}
},
{
"date": "2023-03-22",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 5.Novartis Pharma N.V.",
"value": {
"role": "bestuurder",
"start_date": "2023-03-22"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "bestuurder",
"start_date": "22/03/2023"
}
},
{
"date": "2023-03-22",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 6.Sanofi Belgium N.V.",
"value": {
"role": "bestuurder",
"start_date": "2023-03-22"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"role": "bestuurder",
"start_date": "22/03/2023"
}
},
{
"date": "2023-03-22",
"type": "auditor_appointment",
"quote": "De Algemene Vergadering bevestigt de herbenoeming voor een periode van drie jaar van de commissaris KPMG Bedrijfsrevisoren BV",
"value": {
"role": "commissaris",
"term": "drie jaar",
"start_date": "22/03/2023"
},
"object": "e1",
"subject": "e8"
},
{
"date": "2023-01-01",
"type": "permanent_representative",
"quote": "UCB Pharma N.V. ... heeft als nieuwe vaste vertegenwoordiger vanaf 01/01/2023 de heer Xavier Hormaechea",
"value": {
"start_date": "01/01/2023"
},
"object": "e9",
"subject": "e10"
},
{
"date": "2023-01-19",
"type": "permanent_representative",
"quote": "GlaxoSmithKline Pharmaceuticals N.V. ... heeft als nieuwe vaste vertegenwoordiger vanat 19/01/2023 mevrouw Emmanuelle Boishardy",
"value": {
"start_date": "19/01/2023"
},
"object": "e4",
"subject": "e12"
},
{
"date": "2023-04-19",
"type": "board_meeting",
"quote": "VERGADERING VAN DE RAAD VAN BESTUUR VAN 19 APRIL 2023",
"value": "19/04/2023",
"object": null,
"subject": "e1"
},
{
"date": "2023-04-19",
"type": "officer_appointment",
"quote": "Op de Raad van Bestuur van 19 april 2023 werd de heer Fr\u00E9d\u00E9ric Clais tot voorzitter van de Raad van Bestuun benoemd.",
"value": {
"role": "voorzitter van de Raad van Bestuur",
"start_date": "2023-04-19"
},
"object": "e1",
"subject": "e14",
"_value_raw": {
"role": "voorzitter van de Raad van Bestuur",
"start_date": "19/04/2023"
}
},
{
"type": "permanent_representative",
"quote": "UCB Pharma N.V. (BE 0403.096.168) heeft als nieuwe vaste vertegenwoordiger vanaf 01/01/2023 de heer Xavier Hormaechea in opvolging van de heer Willy Cnops.",
"value": {
"end_date": "01/01/2023"
},
"object": "e9",
"subject": "e11"
},
{
"type": "permanent_representative",
"quote": "GlaxoSmithKline Pharmaceuticals N.V. (BE 0403.066.474) heeft als nieuwe vaste vertegenwoordiger vanat 19/01/2023 mevrouw Emmanuelle Boishardy, in opvolging van mevrouw Sabena Solomon.",
"value": {
"end_date": "19/01/2023"
},
"object": "e4",
"subject": "e13"
}
],
"act_meta": {
"outcome": "corrected",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 2632,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Terhulpsesteenweg 166, 1170 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0400.165.679",
"kind": "company",
"name": "AstraZeneca N.V.",
"attrs": {
"seat": "Alfons Gossetlaan 40 bus 201, 1702 Groot-Bijgaarden"
}
},
{
"id": "e3",
"kbo": "0403.075.184",
"kind": "company",
"name": "Bristol-Myers Squibb Belgium N.V.",
"attrs": {
"seat": "avenue de Finlande 4 Bte 48, 1420 Braine-L\u0027Alleud"
}
},
{
"id": "e4",
"kbo": "0403.066.474",
"kind": "company",
"name": "GlaxoSmithKline Pharmaceuticals N.V.",
"attrs": {
"seat": "avenue Pascal 2-4-6, 1300 Wavre"
}
},
{
"id": "e5",
"kbo": "0415.283.427",
"kind": "company",
"name": "Janssen-Cilag N.V.",
"attrs": {
"seat": "Antwerpseweg 15-17, 2340 Beerse"
}
},
{
"id": "e6",
"kbo": "0459.093.476",
"kind": "company",
"name": "Novartis Pharma N.V.",
"attrs": {
"seat": "Medialaan 40 bus 1, 1800 Vilvoorde"
}
},
{
"id": "e7",
"kbo": "0464.435.901",
"kind": "company",
"name": "Sanofi Belgium N.V.",
"attrs": {
"seat": "Leonardo Da Vincilaan 19, 1831 Diegem"
}
},
{
"id": "e8",
"kbo": "0419.122.548",
"kind": "company",
"name": "KPMG Bedrijfsrevisoren BV",
"attrs": {
"seat": "Bourgetlaan 40, 1130 Brussel"
}
},
{
"id": "e9",
"kbo": "0403.096.168",
"kind": "company",
"name": "UCB Pharma N.V.",
"attrs": {}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Xavier Hormaechea",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Willy Cnops",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Emmanuelle Boishardy",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Sabena Solomon",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Fr\u00E9d\u00E9ric Clais",
"attrs": {}
},
{
"id": "e15",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {}
}
]
}11-05-2023 Act object · General meeting · Officer reappointment · Auditor appointment
- Act object: Nouveaux administrateurs et commissaire - nouveaux représentants permanents des administrateurs - Nomination président · Association Générale de l'Industrie du Médicament
- Filing: 03/05/2023 · Association Générale de l'Industrie du Médicament
- General meeting: 22/03/2023 · Association Générale de l'Industrie du Médicament
- Officer reappointment: role: administrateur · AstraZeneca S.A.
- Officer reappointment: role: administrateur · Bristol-Myers Squibb Belgium S.A.
- Officer reappointment: role: administrateur · GlaxoSmithKline Pharmaceuticals S.A.
- Officer reappointment: role: administrateur · Janssen-Cilag S.A.
- Officer reappointment: role: administrateur · Novartis Pharma S.A.
- Officer reappointment: role: administrateur · Sanofi Belgium S.A.
- Auditor appointment: role: commissaire, term: trois ans · KPMG Réviseurs d'Entreprises SRL
- Permanent representative: start_date: 01/01/2023 · Xavier Hormaechea
- Permanent representative: start_date: 19/01/2023 · Emmanuelle Boishardy
- Board meeting: 19/04/2023 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Président du Conseil d'administration · Frédéric Clais
Summary:
Act object · General meeting · Officer reappointment · Auditor appointment
Technical details
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte : Nouveaux administrateurs et commissaire - nouveaux repr\u00E9sentants permanents des administrateurs - Nomination pr\u00E9sident",
"value": "Nouveaux administrateurs et commissaire - nouveaux repr\u00E9sentants permanents des administrateurs - Nomination pr\u00E9sident",
"object": null,
"subject": "e1"
},
{
"date": "2023-05-03",
"type": "filing",
"quote": "neergelegd/ontvangen op 03 MEI 2023",
"value": "03/05/2023",
"object": null,
"subject": "e1"
},
{
"date": "2023-03-22",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE ORDINAIRE DU 22 MARS 2023",
"value": "22/03/2023",
"object": null,
"subject": "e1"
},
{
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1.AstraZeneca S.A.",
"value": {
"role": "administrateur"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "administrateur",
"term": null,
"start_date": null
}
},
{
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 2.Bristol-Myers Squibb Belgium S.A.",
"value": {
"role": "administrateur"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "administrateur",
"term": null,
"start_date": null
}
},
{
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 3.GlaxoSmithKline Pharmaceuticals S.A.",
"value": {
"role": "administrateur"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "administrateur",
"term": null,
"start_date": null
}
},
{
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 4.Janssen-Cilag S.A.",
"value": {
"role": "administrateur"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "administrateur",
"term": null,
"start_date": null
}
},
{
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 5.Novartis Pharma S.A.",
"value": {
"role": "administrateur"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "administrateur",
"term": null,
"start_date": null
}
},
{
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 5.Sanofi Belgium S.A.",
"value": {
"role": "administrateur"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"role": "administrateur",
"term": null,
"start_date": null
}
},
{
"type": "auditor_appointment",
"quote": "L\u0027Assembl\u00E9e g\u00E9n\u00E9rale confirme la reconduction de la nomination pour une p\u00E9riode de trois ans du commissaire KPMG R\u00E9viseurs d\u0027Entreprises SRL",
"value": {
"role": "commissaire",
"term": "trois ans",
"start_date": null
},
"object": "e1",
"subject": "e8"
},
{
"date": "2023-01-01",
"type": "permanent_representative",
"quote": "UCB Pharma N.V. ... a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 01/01/2023 Monsieur Xavier Hormaechea",
"value": {
"start_date": "01/01/2023"
},
"object": "e9",
"subject": "e10"
},
{
"date": "2023-01-19",
"type": "permanent_representative",
"quote": "GlaxoSmithKline Pharmaceuticals N.V. ... a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 19/01/2023 Madame Emmanuelle Boishardy",
"value": {
"start_date": "19/01/2023"
},
"object": "e12",
"subject": "e13"
},
{
"date": "2023-04-19",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 19 AVRIL 2023",
"value": "19/04/2023",
"object": null,
"subject": "e1"
},
{
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 19 avril 2023, Monsieur Fr\u00E9d\u00E9ric Clais a \u00E9t\u00E9 d\u00E9sign\u00E9 comme Pr\u00E9sident du Conseil d\u0027administration.",
"value": {
"role": "Pr\u00E9sident du Conseil d\u0027administration"
},
"object": "e1",
"subject": "e15",
"_value_raw": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"term": null,
"start_date": null
}
}
],
"act_meta": {
"outcome": "clean",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 2645,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 Bruxelles",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0400.165.679",
"kind": "company",
"name": "AstraZeneca S.A.",
"attrs": {
"seat": "Alfons Gossetlaan 40 bte 201, 1702 Groot-Bijgaarden"
}
},
{
"id": "e3",
"kbo": "0403.075.184",
"kind": "company",
"name": "Bristol-Myers Squibb Belgium S.A.",
"attrs": {
"seat": "avenue de Finlande 4 Bte 48, 1420 Braine-L\u0027Alleud"
}
},
{
"id": "e4",
"kbo": "0403.066.474",
"kind": "company",
"name": "GlaxoSmithKline Pharmaceuticals S.A.",
"attrs": {
"seat": "avenue Pascal 2-4-6, 1300 Wavre"
}
},
{
"id": "e5",
"kbo": "0415.283.427",
"kind": "company",
"name": "Janssen-Cilag S.A.",
"attrs": {
"seat": "Antwerpseweg 15-17, 2340 Beerse"
}
},
{
"id": "e6",
"kbo": "0459.093.476",
"kind": "company",
"name": "Novartis Pharma S.A.",
"attrs": {
"seat": "Medialaan 40, bte 1, 1800 Vilvoorde"
}
},
{
"id": "e7",
"kbo": "0464.435.901",
"kind": "company",
"name": "Sanofi Belgium S.A.",
"attrs": {
"seat": "Leonardo Da Vincilaan 19, 1831 Diegem"
}
},
{
"id": "e8",
"kbo": "0419.122.548",
"kind": "company",
"name": "KPMG R\u00E9viseurs d\u0027Entreprises SRL",
"attrs": {
"seat": "avenue du Bourget 40, 1130 Bruxelles"
}
},
{
"id": "e9",
"kbo": "0403.096.168",
"kind": "company",
"name": "UCB Pharma N.V.",
"attrs": {}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Xavier Hormaechea",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Willy Cnops",
"attrs": {}
},
{
"id": "e12",
"kbo": "0403.066.474",
"kind": "company",
"name": "GlaxoSmithKline Pharmaceuticals N.V.",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Emmanuelle Boishardy",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Sabena Solomon",
"attrs": {}
},
{
"id": "e15",
"kbo": null,
"kind": "person",
"name": "Fr\u00E9d\u00E9ric Clais",
"attrs": {}
}
]
}2022
28-07-2022 Capital increase of €819,225,260.40 to €7,804,773,797.45
- €6.985.548.537,05 → €7.804.773.797,45
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 819225260.4,
"currency": "EUR",
"after_eur": 7804773797.45,
"delta_eur": 819225260.4,
"before_eur": 6985548537.05,
"amount_type": "kapitaal_effectief",
"effective_date": "2022-07-15",
"evidence_quote": "L\u2019assembl\u00E9e d\u00E9cide d\u2019augmenter le capital social \u00E0 concurrence de 819.225.260,40 EUR pour le porter de 6.985.548.537,05 EUR \u00E0 7.804.773.797,45 EUR r\u00E9mun\u00E9r\u00E9 par l\u2019\u00E9mission de 98.433.814 nouvelles actions... Ces actions nouvelles seront attribu\u00E9es, enti\u00E8rement lib\u00E9r\u00E9es, \u00E0 la soci\u00E9t\u00E9 anonyme UCB, en r\u00E9mun\u00E9ration de l\u0027apport en nature par cette derni\u00E8re de la note intra-groupe d\u2019un montant total de 819.225.268,29 EUR au 15 juillet 2022",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}23-06-2022 2 reappointed
- Kirsten Lund-Jürgensen, Bestuurder
- Caroline Vancoillie, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Kirsten Lund-J\u00FCrgensen",
"address": null,
"birth_date": null
},
"evidence_quote": "de renouveler les mandats d\u0027administrateurs de Mesdames Kirsten Lund-J\u00FCrgensen et Caroline Vancoillie pour un terme de six ans"
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Caroline Vancoillie",
"address": null,
"birth_date": null
},
"evidence_quote": "de renouveler les mandats d\u0027administrateurs de Mesdames Kirsten Lund-J\u00FCrgensen et Caroline Vancoillie pour un terme de six ans"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}2021
09-07-2021 1 director appointed, 1 resigning
- Anton Nuttens, Commissaris
- Romain Seffer, Commissaris
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "commissaris_out",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Romain Seffer",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "PwC R\u00E9viseurs d\u0027entreprises SRL",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-07-01",
"evidence_quote": "d\u0027acter la fin du mandat de PwC R\u00E9viseurs d\u0027entreprises SRL, ayant son si\u00E8ge social \u00E0 Woluwedal 18, Sint-Stevens-Woluwe, repr\u00E9sent\u00E9e par Romain Seffer, en qualit\u00E9 de commissaire de la Soci\u00E9t\u00E9 au moment de l\u0027entr\u00E9e en vigueur des pr\u00E9sentes d\u00E9cisions unanimes par \u00E9crit;"
},
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Anton Nuttens",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0428837889",
"name": "Mazars R\u00E9viseurs d\u0027Entreprises SC",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-07-01",
"evidence_quote": "de nommer Mazars R\u00E9viseurs d\u0027Entreprises SC, ayant son si\u00E8ge social \u00E0 Avenue du Boulevard 21, box 8, 1210 Saint-Josse-ten-Noode (Bruxelles) et portant le num\u00E9ro d\u0027entreprise 0428.837.889, comme nouveau commissaire pour une dur\u00E9e de 3 ans, jusqu\u0027\u00E0 et y compris l\u0027assembl\u00E9e g\u00E9n\u00E9rale appel\u00E9e \u00E0 statuer s"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}09-07-2021 Change in the board of directors
Summary:
v3.2
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "NV"
}
}09-07-2021 Change in the board of directors
Summary:
v3.2
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}22-01-2021 Capital increase of €6,985,548,537.05 to €6,985,548,537.05
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 6985548537.05,
"currency": "EUR",
"after_eur": 6985548537.05,
"delta_eur": 6985548537.05,
"before_eur": null,
"amount_type": "kapitaal_effectief",
"effective_date": "2020-12-18",
"evidence_quote": "ARTICLE 5.- Le capital est fix\u00E9 \u00E0 six milliards neuf cent quatre-vingt-cinq millions cinq cent quarante-huit mille cinq cent trente-sept euros et cinq cents (6.985.548.537,05 EUR) et est repr\u00E9sent\u00E9 par 839.351.526 actions sans d\u00E9signation de valeur nominale, num\u00E9rot\u00E9s de 1 \u00E0 839.351.526 repr\u00E9sentant chacune 1/839.351.526e du capital social, enti\u00E8rement lib\u00E9r\u00E9es.",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}2020
30-12-2020 Capital increase of €5,751,269,288.48 to €6,985,548,537.05
- €1.234.279.248,57 → €6.985.548.537,05
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 5751269288.48,
"currency": "EUR",
"after_eur": 6985548537.05,
"delta_eur": 5751269288.48,
"before_eur": 1234279248.57,
"amount_type": "kapitaal_effectief",
"effective_date": "2020-12-18",
"evidence_quote": "L\u2019assembl\u00E9e d\u00E9cide d\u2019augmenter le capital social \u00E0 concurrence de 5.751.269.288,48 EUR pour le porter de 1.234.279.248,57 EUR \u00E0 6.985.548.537,05 EUR par l\u2019\u00E9mission de 691.046.183 nouvelles actions... Ces actions nouvelles seront attribu\u00E9es, enti\u00E8rement lib\u00E9r\u00E9es, \u00E0 la soci\u00E9t\u00E9 anonyme UCB, en r\u00E9mun\u00E9ration de l\u0027apport par cette derni\u00E8re du billet \u00E0 ordre",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}12-11-2020 1 director appointed, 1 resigning
- Geoffroy Folie, Dagelijks bestuur
- Eric Browaeys, Dagelijks bestuur
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_in",
"role": "dagelijks_bestuur",
"person": {
"rrn": null,
"name": "Geoffroy Folie",
"address": null,
"birth_date": null
},
"effective_date": "2020-10-19",
"evidence_quote": "Le Conseil d\u0027Administration d\u00E9cide de nommer, avec effet au 19 octobre 2020, Geoffroy Folie, avec adresse professionnelle, Chemin du Foriest 1 \u00E0 1420 Braine-l\u0027Alleud, en qualit\u00E9 de d\u00E9l\u00E9gu\u00E9 charg\u00E9 de la gestion journali\u00E8re de la soci\u00E9t\u00E9, avec pouvoir d\u0027agir seul, en remplacement de Eric Browaeys dont"
},
{
"kind": "director_out",
"role": "dagelijks_bestuur",
"person": {
"rrn": null,
"name": "Eric Browaeys",
"address": null,
"birth_date": null
},
"effective_date": "2020-10-19",
"evidence_quote": "Le Conseil d\u0027Administration d\u00E9cide de nommer, avec effet au 19 octobre 2020, Geoffroy Folie, avec adresse professionnelle, Chemin du Foriest 1 \u00E0 1420 Braine-l\u0027Alleud, en qualit\u00E9 de d\u00E9l\u00E9gu\u00E9 charg\u00E9 de la gestion journali\u00E8re de la soci\u00E9t\u00E9, avec pouvoir d\u0027agir seul, en remplacement de Eric Browaeys dont"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}23-06-2020 2 reappointed
- Jean-Christophe Tellier, Bestuurder
- Charl van Zyl, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean-Christophe Tellier",
"address": null,
"birth_date": null
},
"evidence_quote": "d\u00E9cident de renouveler les mandats d\u0027administrateurs de Messieurs Jean-Christophe Tellier et Charl van Zyl pour un terme de trois ans"
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Charl van Zyl",
"address": null,
"birth_date": null
},
"evidence_quote": "d\u00E9cident de renouveler les mandats d\u0027administrateurs de Messieurs Jean-Christophe Tellier et Charl van Zyl pour un terme de trois ans"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}02-01-2020 Jacques Marbehant appointed as daily management
- Jacques Marbehant, Dagelijks bestuur
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_in",
"role": "dagelijks_bestuur",
"person": {
"rrn": null,
"name": "Jacques Marbehant",
"address": null,
"birth_date": null
},
"effective_date": "2019-11-22",
"evidence_quote": "Le Conseil d\u0027Administration d\u00E9cide de nommer, avec effet au 22 novembre 2019, Jacques Marbehant, avec adresse professionnelle, Chemin du Foriest 1 \u00E0 1420 Braine-l\u0027Alleud, en qualit\u00E9 de d\u00E9l\u00E9gu\u00E9 charg\u00E9 de la gestion journali\u00E8re de la soci\u00E9t\u00E9, avec pouvoir d\u0027agir seul."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}2019
23-08-2019 Kirsten LUND-JÜRGENSEN appointed as director
- Kirsten LUND-JÜRGENSEN, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Kirsten LUND-J\u00DCRGENSEN",
"address": null,
"birth_date": null
},
"effective_date": "2019-07-18",
"evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 536 \u00A7 1 du Cade des Soci\u00E9t\u00E9s, les actionnaires: d\u00E9cident \u00E0 l\u0027unanimit\u00E9 de nommer, avec effet imm\u00E9diat, Kirsten LUND-J\u00DCRGENSEN, avec adresse! professionnelle, Chemin du Foriest 1 \u00E0 1420 Braine-l\u0027Alleud, en qualit\u00E9 d\u0027Administrateur additionnel de la Soci\u00E9t\u00E9."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "NV"
}
}09-07-2019 General meeting · Officer reappointment · Board meeting · Officer appointment
- Publication: 09/07/2019
- Filing: 28/06/2019
- General meeting: 27/03/2019
- Officer reappointment: date: 2019-03-27, role: Raad van Bestuur · MSD Belgium N.V.
- Officer reappointment: date: 2019-03-27, role: Raad van Bestuur · Roche N.V.
- Officer reappointment: date: 2019-03-27, role: Raad van Bestuur · Chiesi N.V.
- Officer reappointment: date: 2019-03-27, role: Raad van Bestuur · UCB Pharma N.V.
- Board meeting: 24/04/2019
- Officer appointment: role: ondervoorzitter van de Raad van Bestuur, start_date: 2019-04-24 · Celgene
- Permanent representative · Michel Collard
- Officer resignation: date: 2019-04-24, role: ondervoorzitter van de Raad van Bestuur · MSD Belgium N.V.
- Permanent representative · Clarisse Lhoste
- Officer appointment: role: CEO belast met het dagelijks bestuur · Catherine Rutten
Summary:
General meeting · Officer reappointment · Board meeting · Officer appointment
Technical details
{
"facts": [
{
"date": "2019-07-09",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 09/07/2019",
"value": "09/07/2019",
"object": null,
"subject": null
},
{
"date": "2019-06-28",
"type": "filing",
"quote": "vangen op 28 JUNI 2019 ter griffie van de Nederlandstalige ondernemingsrechtbank Brusss",
"value": "28/06/2019",
"object": null,
"subject": null
},
{
"date": "2019-03-27",
"type": "general_meeting",
"quote": "ALGEMENE VERGADERING VAN 27 MAART 2019",
"value": "27/03/2019",
"object": null,
"subject": null
},
{
"date": "2019-03-27",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. MSD Belgium N.V.",
"value": {
"date": "2019-03-27",
"role": "Raad van Bestuur"
},
"object": null,
"subject": "e1",
"_value_raw": {
"date": "27/03/2019",
"role": "Raad van Bestuur"
}
},
{
"date": "2019-03-27",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 2. Roche N.V.",
"value": {
"date": "2019-03-27",
"role": "Raad van Bestuur"
},
"object": null,
"subject": "e2",
"_value_raw": {
"date": "27/03/2019",
"role": "Raad van Bestuur"
}
},
{
"date": "2019-03-27",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 3. Chiesi N.V.",
"value": {
"date": "2019-03-27",
"role": "Raad van Bestuur"
},
"object": null,
"subject": "e3",
"_value_raw": {
"date": "27/03/2019",
"role": "Raad van Bestuur"
}
},
{
"date": "2019-03-27",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 4. UCB Pharma N.V.",
"value": {
"date": "2019-03-27",
"role": "Raad van Bestuur"
},
"object": null,
"subject": "e4",
"_value_raw": {
"date": "27/03/2019",
"role": "Raad van Bestuur"
}
},
{
"date": "2019-04-24",
"type": "board_meeting",
"quote": "VERGADERING VAN DE RAAD VAN BESTUUR VAN 24 APRIL 2019",
"value": "24/04/2019",
"object": null,
"subject": null
},
{
"date": "2019-04-24",
"type": "officer_appointment",
"quote": "Op de Raad van Bestuur van 24 april 2019 werd Celgene, vertegenwoordigd door Michel Collard, verkozen tot nieuwe ondervoorzitter van de Raad van Bestuur",
"value": {
"role": "ondervoorzitter van de Raad van Bestuur",
"start_date": "2019-04-24"
},
"object": null,
"subject": "e5",
"_value_raw": {
"role": "ondervoorzitter van de Raad van Bestuur",
"start_date": "24/04/2019"
}
},
{
"type": "permanent_representative",
"quote": "Celgene, vertegenwoordigd door Michel Collard",
"value": null,
"object": "e5",
"subject": "e6"
},
{
"date": "2019-04-24",
"type": "officer_resignation",
"quote": "in opvolging van MSD Belgium, vertegenwoordigd door Clarisse Lhoste",
"value": {
"date": "2019-04-24",
"role": "ondervoorzitter van de Raad van Bestuur"
},
"object": null,
"subject": "e1",
"_value_raw": {
"date": "24/04/2019",
"role": "ondervoorzitter van de Raad van Bestuur"
}
},
{
"type": "permanent_representative",
"quote": "MSD Belgium, vertegenwoordigd door Clarisse Lhoste",
"value": null,
"object": "e1",
"subject": "e7"
},
{
"type": "officer_appointment",
"quote": "Catherine Rutten CEO belast met het dagelijks bestuur",
"value": {
"role": "CEO belast met het dagelijks bestuur"
},
"object": null,
"subject": "e8"
}
],
"act_meta": {
"outcome": "corrected",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1672,
"truncated": false
},
"entities": [
{
"id": "e0",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Terhulpsesteenweg 166, 1170 BRUSSEL",
"legal_form": "Vereniging zonder winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e1",
"kbo": "0406.820.770",
"kind": "company",
"name": "MSD Belgium N.V.",
"attrs": {
"seat": "Lynx Binnenhof 5, 1200 Sint-Lambrechts-Woluwe"
}
},
{
"id": "e2",
"kbo": "0403.088.151",
"kind": "company",
"name": "Roche N.V.",
"attrs": {
"seat": "Dantestraat 75, 1070 Anderlecht"
}
},
{
"id": "e3",
"kbo": "0826.654.883",
"kind": "company",
"name": "Chiesi N.V.",
"attrs": {
"seat": "Telecomlaan 9, 1831 Diegem"
}
},
{
"id": "e4",
"kbo": "0403.096.168",
"kind": "company",
"name": "UCB Pharma N.V.",
"attrs": {
"seat": "Researchdreef 60, 1070 Anderlecht"
}
},
{
"id": "e5",
"kbo": null,
"kind": "company",
"name": "Celgene",
"attrs": {}
},
{
"id": "e6",
"kbo": null,
"kind": "person",
"name": "Michel Collard",
"attrs": {}
},
{
"id": "e7",
"kbo": null,
"kind": "person",
"name": "Clarisse Lhoste",
"attrs": {}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "Catherine Rutten",
"attrs": {}
}
]
}09-07-2019 General meeting · Officer reappointment · Board meeting · Officer appointment
- Publication: 2019
- Filing: 28/05/2019
- General meeting: 27/03/2019
- Officer reappointment: date: 2019-03-27, role: Membre du Conseil d'administration · MSD Belgium S.A.
- Officer reappointment: date: 2019-03-27, role: Membre du Conseil d'administration · Roche S.A.
- Officer reappointment: date: 2019-03-27, role: Membre du Conseil d'administration · Chiesi S.A.
- Officer reappointment: date: 2019-03-27, role: Membre du Conseil d'administration · UCB Belgium S.A.
- Board meeting: 24/04/2019
- Officer appointment: role: Vice-Président du Conseil d'administration, start_date: 2019-04-24 · Celgene
- Permanent representative · Michel Collard
- Permanent representative · Clarisse Lhoste
Summary:
General meeting · Officer reappointment · Board meeting · Officer appointment
Technical details
{
"facts": [
{
"date": "2019-07-09",
"type": "publication",
"quote": "2019 - Annexes du Moniteur belge",
"value": "2019",
"object": null,
"subject": null
},
{
"date": "2019-05-28",
"type": "filing",
"quote": "neergelegd/ontvangen op 28 JUMM 2019",
"value": "28/05/2019",
"object": null,
"subject": null
},
{
"date": "2019-03-27",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 27 MARS 2019",
"value": "27/03/2019",
"object": null,
"subject": null
},
{
"date": "2019-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. MSD Belgium S.A.",
"value": {
"date": "2019-03-27",
"role": "Membre du Conseil d\u0027administration"
},
"object": null,
"subject": "e1",
"_value_raw": {
"date": "27/03/2019",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2019-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 2. Roche S.A.",
"value": {
"date": "2019-03-27",
"role": "Membre du Conseil d\u0027administration"
},
"object": null,
"subject": "e2",
"_value_raw": {
"date": "27/03/2019",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2019-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 3. Chiesi S.A.",
"value": {
"date": "2019-03-27",
"role": "Membre du Conseil d\u0027administration"
},
"object": null,
"subject": "e3",
"_value_raw": {
"date": "27/03/2019",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2019-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 4. UCB Belgium S.A.",
"value": {
"date": "2019-03-27",
"role": "Membre du Conseil d\u0027administration"
},
"object": null,
"subject": "e4",
"_value_raw": {
"date": "27/03/2019",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2019-04-24",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 24 AVRIL 2019",
"value": "24/04/2019",
"object": null,
"subject": null
},
{
"date": "2019-04-24",
"type": "officer_appointment",
"quote": "Celgene ... a \u00E9t\u00E9 \u00E9lue nouveau Vice-Pr\u00E9sident du Conseil d\u0027administration",
"value": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"start_date": "2019-04-24"
},
"object": null,
"subject": "e5",
"_value_raw": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"start_date": "24/04/2019"
}
},
{
"type": "permanent_representative",
"quote": "Celgene, repr\u00E9sent\u00E9e par Michel Collard",
"value": null,
"object": "e5",
"subject": "e6"
},
{
"type": "permanent_representative",
"quote": "MSD Belgium, repr\u00E9sent\u00E9e par Clarisse Lhoste",
"value": null,
"object": "e1",
"subject": "e7"
}
],
"act_meta": {
"outcome": "corrected",
"postfix": [
"publication date None -\u003E edition 2019-07-09"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1695,
"truncated": false
},
"entities": [
{
"id": "e0",
"kbo": "0407.622.902",
"kind": "company",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 BRUXELLES",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e1",
"kbo": "0406.820.770",
"kind": "company",
"name": "MSD Belgium S.A.",
"attrs": {
"seat": "Clos du Lynx 5, 1200 Woluwe-Saint-Lambert"
}
},
{
"id": "e2",
"kbo": "0403.088.151",
"kind": "company",
"name": "Roche S.A.",
"attrs": {
"seat": "rue Dante 75, 1070 Anderlecht"
}
},
{
"id": "e3",
"kbo": "0826.654.883",
"kind": "company",
"name": "Chiesi S.A.",
"attrs": {
"seat": "Telecomlaan 9, 1831 Diegem"
}
},
{
"id": "e4",
"kbo": "0403.096.168",
"kind": "company",
"name": "UCB Belgium S.A.",
"attrs": {
"seat": "All\u00E9e de la Recherche 60, 1070 Anderlecht"
}
},
{
"id": "e5",
"kbo": null,
"kind": "company",
"name": "Celgene",
"attrs": {}
},
{
"id": "e6",
"kbo": null,
"kind": "person",
"name": "Michel Collard",
"attrs": {}
},
{
"id": "e7",
"kbo": null,
"kind": "person",
"name": "Clarisse Lhoste",
"attrs": {}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "Catherine Rutten",
"attrs": {}
}
]
}07-06-2019 1 resigning, 1 reappointed
- Cleo Ricci, Bestuurder
- Caroline Vancoillie, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Cleo Ricci",
"address": null,
"birth_date": null
},
"effective_date": "2019-03-31",
"evidence_quote": "Le Conseil est inform\u00E9 que Cleo Ricci a quitt\u00E9 UCB et accepte sa lettre de d\u00E9mission en qualit\u00E9 d\u0027Adminitrateur et g\u00E9rant charg\u00E9 de la gestion joumali\u00E8re avec effet au 31 mars 2019."
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Caroline Vancoillie",
"address": null,
"birth_date": null
},
"evidence_quote": "d\u00E9cident de renouveler le mandat d\u0027administrateur de Madame Caroline Vancoillie pour un terme de trois ans"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}03-05-2019 Capital increase of €305,116,347.97 to €1,234,279,248.57
- €929.162.900,60 → €1.234.279.248,57
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 305116347.97,
"currency": "EUR",
"after_eur": 1234279248.57,
"delta_eur": 305116347.97,
"before_eur": 929162900.6,
"amount_type": "kapitaal_effectief",
"effective_date": "2019-04-29",
"evidence_quote": "L\u2019assembl\u00E9e d\u00E9cide d\u2019augmenter le capital social \u00E0 concurrence de 305.116.347,97 EUR pour le porter de 929.162.900,60 EUR \u00E0 1.234.279.248,57 EUR par l\u2019\u00E9mission de 36.661.383 nouvelles actions... attribu\u00E9es, enti\u00E8rement lib\u00E9r\u00E9es, \u00E0 la soci\u00E9t\u00E9 anonyme UCB, en r\u00E9mun\u00E9ration de l\u0027apport par cette derni\u00E8re d\u0027une partie du pr\u00EAt",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}05-02-2019 Benoit Stevens resigns as daily management
- Benoit Stevens, Dagelijks bestuur
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "dagelijks_bestuur",
"person": {
"rrn": null,
"name": "Benoit Stevens",
"address": null,
"birth_date": null
},
"effective_date": "2018-04-01",
"evidence_quote": "Le Conseil est inform\u00E9 que Benoit Stevens a d\u00E9missionn\u00E9 en qualit\u00E9 de d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion de la Soci\u00E9t\u00E9 \u00E0 partir du 1 avril 2018."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}2018
27-08-2018 1 director appointed, 1 resigning, 1 reappointed
- Caroline Vancoillie, Bestuurder
- Benoit Stevens, Bestuurder
- Romain Seffer, Commissaris
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Benoit Stevens",
"address": null,
"birth_date": null
},
"effective_date": "2018-04-19",
"evidence_quote": "d\u00E9mission volontaire de Monsieur Benoit Stevens comme administrateur de la Soci\u00E9t\u00E9 d\u00E8s le 19 avril 2018;"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Caroline Vancoillie",
"address": null,
"birth_date": null
},
"evidence_quote": "nomination en tant qu\u0027administrateur de la Soci\u00E9t\u00E9, \u00E0 titre gratuit et prenant fin \u00E0 l\u0027assembl\u00E9e g\u00E9n\u00E9rale des actionnaires de 2019: Madame Caroline Vancoillie avec adresse personnelle \u00E0 All\u00E9e de la Recherche 60, 1070 Bruxelles."
},
{
"kind": "commissaris_renew",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Romain Seffer",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "SCCRL PwC Reviseurs d\u0027Entreprises",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "renouvellement du mandat de la SCCRL PwC Reviseurs d\u0027Entreprises, ayant son si\u00E8ge social \u00E0 1932 Sint-Stevens-Woluwe, Woluwedal 18, en qualit\u00E9 de commissaire pour un terme de trois ans. Cette soci\u00E9t\u00E9 d\u00E9signe Monsieur Romain Seffer, r\u00E9viseur d\u0027entreprises, comme repr\u00E9sentant permanent pour la repr\u00E9sen"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}2017
25-09-2017 Fabrice Enderlin resigns as director
- Fabrice Enderlin, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Fabrice Enderlin",
"address": null,
"birth_date": null
},
"effective_date": "2017-05-10",
"evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 536 du Code des soci\u00E9t\u00E9s, les Actionnaires, \u00E0 l\u0027unanimit\u00E9 sont inform\u00E9s que le mandat de Fabrice Enderiin en qualit\u00E9 d\u0027Administrateur a expir\u00E9 lors de l\u0027Assembl\u00E9e G\u00E9n\u00E9rale du 10 mai 2017."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}30-05-2017 1 director appointed, 1 reappointed
- Charl van Zyl, Bestuurder
- Jean-Christophe Tellier, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean-Christophe Tellier",
"address": null,
"birth_date": null
},
"evidence_quote": "decident de renouveler le mandat d\u0027Administrateur de Jean-ChristopheTellier, avec adresse professionnelle All\u00E9e de la Recherche, 60 \u00E0 1070 Bruxelles pour un terme de tro\u00EDs ans."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Charl van Zyl",
"address": null,
"birth_date": null
},
"evidence_quote": "decident de nommer Charl van Zyl, aveo adresse professionnelle All\u00E9e de la Recherche, 60 \u00E0 1070 Bruxelles, en qualit\u00E9 d\u0027Administrateur pour un terme de trois ans;"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}17-02-2017 Mark McDade resigns as director
- Mark McDade, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mark McDade",
"address": null,
"birth_date": null
},
"effective_date": "2016-12-31",
"evidence_quote": "Mark McDade prenant sa retraite au sein du Groupe UCB \u00E0 fin d\u00E9cembre, le Conseil est inform\u00E9 qu\u0027il va \u00E9galement d\u00E9missionner en qualit\u00E9 d\u0027Administrateur avec effet au 31 d\u00E9cembre 2016. Le Conseil accepte la d\u00E9m\u00EDssion de Mark McDade en qualit\u00E9 d\u0027Administrateur de la soci\u00E9t\u00E9 avec effet au 31 d\u00E9cembre "
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}2016
11-05-2016 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 11/05/2016 · Association Générale de l'Industrie du Médicament
- Filing: 29/04/2016 · Association Générale de l'Industrie du Médicament
- General meeting: 18/03/2016 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: administrateur, start_date: 2016-03-18 · Roche S.A.
- Officer appointment: role: administrateur, start_date: 2016-03-18 · Chiesi S.A.
- Officer reappointment: role: administrateur, start_date: 2016-03-18 · MSD Belgium S.A.
- Officer reappointment: role: administrateur, start_date: 2016-03-18 · UCB Belgium S.A.
- Officer resignation: date: 2016-03-18, role: administrateur · AstraZeneca S.A.
- Officer resignation: date: 2016-03-18, role: administrateur · Baxter Belgium SPRL
- Officer resignation: date: 2016-03-18, role: administrateur · Bracco Imaging Europe B.V.
- Statute amendment: article: 14, description: Poids des votes, procuration et procédure de vote · Association Générale de l'Industrie du Médicament
- Statute amendment: article: 16, description: Composition du Conseil d'administration · Association Générale de l'Industrie du Médicament
- Statute amendment: article: 21, description: Mandats · Association Générale de l'Industrie du Médicament
- Statute amendment: article: 27ter, description: Organes (groupe pharma.be animal health) · Association Générale de l'Industrie du Médicament
- Statute amendment: article: 33, description: Conditions d'admission et durée de mandat exceptionnelle · Association Générale de l'Industrie du Médicament
Summary:
General meeting · Officer appointment · Officer reappointment · Officer resignation
Technical details
{
"facts": [
{
"date": "2016-05-11",
"type": "publication",
"quote": "Bijlagen bij het Belgisch. Staatshlad -11/05/2016-",
"value": "11/05/2016",
"object": null,
"subject": "e1"
},
{
"date": "2016-04-29",
"type": "filing",
"quote": "neergelegd/entvangen op 29 APR, 2016",
"value": "29/04/2016",
"object": null,
"subject": "e1"
},
{
"date": "2016-03-18",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 18 MARS 2016",
"value": "18/03/2016",
"object": null,
"subject": "e1"
},
{
"date": "2016-03-18",
"type": "officer_appointment",
"quote": "Nomination de: 1. Roche S.A.",
"value": {
"role": "administrateur",
"start_date": "2016-03-18"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "administrateur",
"start_date": "18/03/2016"
}
},
{
"date": "2016-03-18",
"type": "officer_appointment",
"quote": "Nomination de: 2. Chiesi S.A.",
"value": {
"role": "administrateur",
"start_date": "2016-03-18"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "administrateur",
"start_date": "18/03/2016"
}
},
{
"date": "2016-03-18",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. MSD Belgium S.A.",
"value": {
"role": "administrateur",
"start_date": "2016-03-18"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "administrateur",
"start_date": "18/03/2016"
}
},
{
"date": "2016-03-18",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 2. UCB Belgium S.A.",
"value": {
"role": "administrateur",
"start_date": "2016-03-18"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "administrateur",
"start_date": "18/03/2016"
}
},
{
"date": "2016-03-18",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 1. AstraZeneca S.A.",
"value": {
"date": "2016-03-18",
"role": "administrateur"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"date": "18/03/2016",
"role": "administrateur"
}
},
{
"date": "2016-03-18",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 2. Baxter Belgium SPRL",
"value": {
"date": "2016-03-18",
"role": "administrateur"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "18/03/2016",
"role": "administrateur"
}
},
{
"date": "2016-03-18",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 3. Bracco Imaging Europe B.V.",
"value": {
"date": "2016-03-18",
"role": "administrateur"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"date": "18/03/2016",
"role": "administrateur"
}
},
{
"type": "statute_amendment",
"quote": "article 14. Poids des votes, procuration et proc\u00E9dure de vote",
"value": {
"article": "14",
"description": "Poids des votes, procuration et proc\u00E9dure de vote"
},
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "article 16. Composition",
"value": {
"article": "16",
"description": "Composition du Conseil d\u0027administration"
},
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "article 21. Mandats",
"value": {
"article": "21",
"description": "Mandats"
},
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "Article 27ter. Organes",
"value": {
"article": "27ter",
"description": "Organes (groupe pharma.be animal health)"
},
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "article 33.",
"value": {
"article": "33",
"description": "Conditions d\u0027admission et dur\u00E9e de mandat exceptionnelle"
},
"object": null,
"subject": "e1"
}
],
"act_meta": {
"outcome": "clean",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 16790,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 BRUXELLES",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0403.088.151",
"kind": "company",
"name": "Roche S.A.",
"attrs": {
"seat": "rue Dante 75, 1070 Anderlecht"
}
},
{
"id": "e3",
"kbo": "0826.654.883",
"kind": "company",
"name": "Chiesi S.A.",
"attrs": {
"seat": "avenue du Bourget 44, 1130 Haren (Bruxelles)"
}
},
{
"id": "e4",
"kbo": "0406.820.770",
"kind": "company",
"name": "MSD Belgium S.A.",
"attrs": {
"seat": "Clos du Lynx 5, 1200 Woluwe-Saint-Lambert"
}
},
{
"id": "e5",
"kbo": "0403.096.168",
"kind": "company",
"name": "UCB Belgium S.A.",
"attrs": {
"seat": "All\u00E9e de la Recherche 60, 1070 Anderlecht"
}
},
{
"id": "e6",
"kbo": "0400.165.679",
"kind": "company",
"name": "AstraZeneca S.A.",
"attrs": {
"seat": "rue Egide Van Ophem 110, 1180 Uccle"
}
},
{
"id": "e7",
"kbo": "0861.155.805",
"kind": "company",
"name": "Baxter Belgium SPRL",
"attrs": {
"seat": "boulevard d\u0027Angleterre 2-4, 1420 Braine l\u0027Alleud"
}
},
{
"id": "e8",
"kbo": "0892.349.322",
"kind": "company",
"name": "Bracco Imaging Europe B.V.",
"attrs": {
"seat": "avenue Pasteur 6, 1300 Wavre"
}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Catherine Rutten",
"attrs": {
"role": "CEO charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}11-04-2016 Change in the board of directors
Summary:
v3.2
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}01-02-2016 2 directors appointed, 3 resigning
- Benoit Stevens, Bestuurder
- Cleo Ricci, Bestuurder
- Anna S. Richo, Bestuurder
- Ismail Kola, Bestuurder
- Detlef Thielgen, Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Anna S. Richo",
"address": null,
"birth_date": null
},
"effective_date": "2016-01-15",
"evidence_quote": "1.acceptent les d\u00E9m\u00EDssions, avec effet imm\u00E9diat, de Anna S. Richo, Ismail Kola et de Detlef Thielgen en qualit\u00E9 d\u0027Administrateurs;"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Ismail Kola",
"address": null,
"birth_date": null
},
"effective_date": "2016-01-15",
"evidence_quote": "1.acceptent les d\u00E9m\u00EDssions, avec effet imm\u00E9diat, de Anna S. Richo, Ismail Kola et de Detlef Thielgen en qualit\u00E9 d\u0027Administrateurs;"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Detlef Thielgen",
"address": null,
"birth_date": null
},
"effective_date": "2016-01-15",
"evidence_quote": "1.acceptent les d\u00E9m\u00EDssions, avec effet imm\u00E9diat, de Anna S. Richo, Ismail Kola et de Detlef Thielgen en qualit\u00E9 d\u0027Administrateurs;"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Benoit Stevens",
"address": null,
"birth_date": null
},
"effective_date": "2016-01-15",
"evidence_quote": "2.d\u00E9cident de nommer, avec effet imm\u00E9diat, Benoit Stevens, domicili\u00E9 rue Alexis Willems 28, 1160 Auderghem, et Cleo Ricci, domicili\u00E9 rue des Aub\u00E9pines 10 \u00E0 7380 Qui\u00E9vrain, en qualit\u00E9 d\u0027Administrateurs pour: un terme de trois ans."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Cleo Ricci",
"address": null,
"birth_date": null
},
"effective_date": "2016-01-15",
"evidence_quote": "2.d\u00E9cident de nommer, avec effet imm\u00E9diat, Benoit Stevens, domicili\u00E9 rue Alexis Willems 28, 1160 Auderghem, et Cleo Ricci, domicili\u00E9 rue des Aub\u00E9pines 10 \u00E0 7380 Qui\u00E9vrain, en qualit\u00E9 d\u0027Administrateurs pour: un terme de trois ans."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.096.168",
"name_full": "UCB PHARMA",
"legal_form": "SA"
}
}First 30 of 48 acts
Credit advice
AI due-diligence brief
Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Coming soon
AI-generated from Checked data; indicative, not legal or investment advice.
Company registry (CBE)
Activities
Vervaardiging van geneesmiddelen21201Vervaardiging van geneesmiddelen21201Vervaardiging van geneesmiddelen24421Groothandel in farmaceutische producten46460Groothandel in farmaceutische en medische artikelen46460Groothandel in farmaceutische producten51460
Primary activity highlighted.
Names & trade names
| Legal nameFR | UCB PHARMA |
Registered office
Researchdreef 60
1070 Anderlecht, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.
Similar companies
ANSELL HEALTHCARE EUROPE
BE 0437.593.328 · Anderlecht
RECKITT BENCKISER (BELGIUM)SA/NV ou RECKITT BENCKISER HEALTHCARE (BELGIUM) NV/SA
BE 0402.184.269 · Anderlecht
APEX
BE 0424.131.213 · Anderlecht
BRUSSELS REPS PHARMA
BE 0480.073.487 · Anderlecht
CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE
BE 0403.057.962 · Anderlecht